JP5721806B2 - 副作用のない抗癌剤 - Google Patents

副作用のない抗癌剤 Download PDF

Info

Publication number
JP5721806B2
JP5721806B2 JP2013237219A JP2013237219A JP5721806B2 JP 5721806 B2 JP5721806 B2 JP 5721806B2 JP 2013237219 A JP2013237219 A JP 2013237219A JP 2013237219 A JP2013237219 A JP 2013237219A JP 5721806 B2 JP5721806 B2 JP 5721806B2
Authority
JP
Japan
Prior art keywords
cancer
irinotecan
dfp
compound
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013237219A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015091765A (ja
Inventor
ヒィ ジン チェン
ヒィ ジン チェン
正和 福島
正和 福島
清 江島
清 江島
ギャリー アシュレー
ギャリー アシュレー
ダニエル ブイ サンティ
ダニエル ブイ サンティ
Original Assignee
Ｄｅｌｔａ−Ｆｌｙ Ｐｈａｒｍａ株式会社
Ｄｅｌｔａ−Ｆｌｙ Ｐｈａｒｍａ株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ｄｅｌｔａ−Ｆｌｙ Ｐｈａｒｍａ株式会社, Ｄｅｌｔａ−Ｆｌｙ Ｐｈａｒｍａ株式会社 filed Critical Ｄｅｌｔａ−Ｆｌｙ Ｐｈａｒｍａ株式会社
Priority to JP2013237219A priority Critical patent/JP5721806B2/ja
Priority to TW102144080A priority patent/TW201513863A/zh
Priority to SG10201703378UA priority patent/SG10201703378UA/en
Priority to CN201480006400.1A priority patent/CN104981245B/zh
Priority to KR1020157021404A priority patent/KR101678881B1/ko
Priority to PCT/JP2014/052877 priority patent/WO2015049883A1/ja
Priority to SG11201506026PA priority patent/SG11201506026PA/en
Publication of JP2015091765A publication Critical patent/JP2015091765A/ja
Application granted granted Critical
Publication of JP5721806B2 publication Critical patent/JP5721806B2/ja
Priority to HK16102091.6A priority patent/HK1214145A1/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Dermatology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2013237219A 2013-10-04 2013-11-15 副作用のない抗癌剤 Expired - Fee Related JP5721806B2 (ja)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP2013237219A JP5721806B2 (ja) 2013-10-04 2013-11-15 副作用のない抗癌剤
TW102144080A TW201513863A (zh) 2013-10-04 2013-12-02 無副作用之抗癌劑
CN201480006400.1A CN104981245B (zh) 2013-10-04 2014-02-07 无副作用的抗癌剂
KR1020157021404A KR101678881B1 (ko) 2013-10-04 2014-02-07 부작용을 가지지 않는 항암제
SG10201703378UA SG10201703378UA (en) 2013-10-04 2014-02-07 Anticancer agent free of adverse reactions
PCT/JP2014/052877 WO2015049883A1 (ja) 2013-10-04 2014-02-07 副作用のない抗癌剤
SG11201506026PA SG11201506026PA (en) 2013-10-04 2014-02-07 Anticancer agent free of adverse reactions
HK16102091.6A HK1214145A1 (zh) 2013-10-04 2016-02-24 無副作用的抗癌劑

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013209574 2013-10-04
JP2013209574 2013-10-04
JP2013237219A JP5721806B2 (ja) 2013-10-04 2013-11-15 副作用のない抗癌剤

Publications (2)

Publication Number Publication Date
JP2015091765A JP2015091765A (ja) 2015-05-14
JP5721806B2 true JP5721806B2 (ja) 2015-05-20

Family

ID=52778484

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013237219A Expired - Fee Related JP5721806B2 (ja) 2013-10-04 2013-11-15 副作用のない抗癌剤

Country Status (7)

Country Link
JP (1) JP5721806B2 (zh)
KR (1) KR101678881B1 (zh)
CN (1) CN104981245B (zh)
HK (1) HK1214145A1 (zh)
SG (2) SG11201506026PA (zh)
TW (1) TW201513863A (zh)
WO (1) WO2015049883A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10111955B2 (en) 2014-12-04 2018-10-30 Delta-Fly Pharma, Inc. PEG derivative
PL3928835T3 (pl) * 2020-05-14 2024-02-12 Delta-Fly Pharma, Inc. Rozpuszczalna w wodzie polimerowa pochodna wenetoklaksu

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4694776B2 (ja) 2003-07-29 2011-06-08 株式会社ヤクルト本社 微小粒子組成物又はリポソーム製剤
PT1675622T (pt) 2003-09-17 2017-09-19 Nektar Therapeutics Pró-fármacos de polímeros de múltiplos braços
CN102395370A (zh) * 2009-04-17 2012-03-28 安龙制药公司 用7-乙基-10-羟基喜树碱的多臂聚合缀合物抑制血管生成的方法
BR112012001395A2 (pt) 2009-07-22 2019-09-24 Enzon Pharmaceuticals Inc metodo para tratar um câncer her2 positivo em um mamifero metodo para aumentar os efetivos de antagonistas do receptor her2 em um mamifero apresentando um cancêr her2 positivo metodo para inibir o crescimento ou proliferação de células her2 positivas em um mamifero
JP5901073B2 (ja) * 2009-11-18 2016-04-06 ネクター セラピューティクス マルチアームポリマー−薬物コンジュゲートの塩形態
CN103755949B (zh) * 2009-12-25 2016-04-13 天津键凯科技有限公司 多臂聚乙二醇衍生物及其与药物的结合物和凝胶
US8754190B2 (en) * 2010-05-05 2014-06-17 Prolynx Llc Controlled release from macromolecular conjugates

Also Published As

Publication number Publication date
HK1214145A1 (zh) 2016-07-22
WO2015049883A1 (ja) 2015-04-09
JP2015091765A (ja) 2015-05-14
CN104981245B (zh) 2017-10-03
CN104981245A (zh) 2015-10-14
KR20150103749A (ko) 2015-09-11
KR101678881B1 (ko) 2016-11-23
SG10201703378UA (en) 2017-05-30
SG11201506026PA (en) 2015-09-29
TW201513863A (zh) 2015-04-16

Similar Documents

Publication Publication Date Title
JP2022166327A (ja) 癌の治療法
RU2315782C2 (ru) Высокомолекулярные производные камптотецинов
US20080045559A1 (en) Tocopherol-modified therapeutic drug compounds
JP6842479B2 (ja) Ｓｎ−３８の徐放性コンジュゲート
US20070207196A1 (en) Tocopherol-modified therapeutic drug compound formulations
US20080248097A1 (en) Polymeric micelles for combination drug delivery
CA3017690C (en) Oligolactic acid conjugates and micelles with enhanced anticancer efficacy
JP6223995B2 (ja) カンプトテシン類と抗癌効果増強剤の結合した高分子化合物及びその用途
ZA200604093B (en) Tocopherol-modified therapeutic drug compounds
JP5721806B2 (ja) 副作用のない抗癌剤
JP5613679B2 (ja) 腹腔内投与用の抗がん剤含有ブロック共重合体、ミセル調製物及びそれを有効成分とする癌治療薬
EP1824485B1 (en) Pharmaceutical formulation for increasing solubility of 10-hydroxycamptothecin compounds in non-aqueous polar solvents
JP6735759B2 (ja) カンプトテシン類高分子誘導体を含有する医薬組成物
RU2697551C2 (ru) Новые производные peg
US20220331437A1 (en) Conjugated inhibitors of dna damage response
JP2011225510A (ja) 新規な抗腫瘍剤
V Yurkovetskiy et al. XMT-1001, A novel biodegradable polyacetal polymer conjugate of camptothecin in clinical development
JP6797182B2 (ja) カンプトテシン類高分子誘導体を含有する医薬製剤
EP2210584A1 (en) Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer

Legal Events

Date Code Title Description
A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150213

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150303

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150324

R150 Certificate of patent or registration of utility model

Ref document number: 5721806

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees